SG11201808541VA - Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use - Google Patents

Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use

Info

Publication number
SG11201808541VA
SG11201808541VA SG11201808541VA SG11201808541VA SG11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA
Authority
SG
Singapore
Prior art keywords
rivig
international
immune
proteins
ste
Prior art date
Application number
SG11201808541VA
Inventor
Yen-Ming Hsu
Jeng-Shin Lee
Hsiu-Ching Chang
Original Assignee
Ab biosciences inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab biosciences inc filed Critical Ab biosciences inc
Publication of SG11201808541VA publication Critical patent/SG11201808541VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111010111110111010111110111111111011001111101111011111 International Bureau ... .1 j (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/172853 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: DO, C07K 19/00 (2006.01) C07K 14/47 (2006.01) HN, KP, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (21) International Application Number: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, PCT/US2017/024650 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (22) International Filing Date: RU, 29 March 2017 (29.03.2017) TH, ZA, ZM, ZW. RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, 62/315,483 30 March 2016 (30.03.2016) US TZ, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: AB BIOSCIENCES, INC. [US/US]; 214 Lin- DK, coin St. Ste 402, Aliston, MA 02134 (US). LV, SM, (72) Inventors: HSU, Yen-Ming; 214 Lincoln St. Ste 402, Al- EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, iston, MA 02134 (US). LEE, Jeng-Shin; 214 Lincoln St. GW, KM, ML, MR, NE, SN, TD, TG). Ste 402, Aliston, MA 02134 (US). CHANG, Hsiu-Ching; Published: 214 Lincoln St. Ste 402, Aliston, MA 02134 (US). — with international search report (Art. 21(3)) (74) Agent: LAZAR, Steven, R.; 234 Broadway, Arlington, before the expiration of the time limit for amending the MA 80709 (US). claims and to be republished in the event of receipt of Designated States (unless otherwise indicated, for every amendments (Rule 48.2(h)) (81) kind of national protection available): AE, AG, AL, AM, _ with sequence listing part of description (Rule 5.2(a)) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, Title: RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND METHODS FOR THEIR (54) AND USE = PRODUCTION (57) : Compositions of recombinant in- FIGURE 1. CONSTRUCTS OF rIVIG MOLECULES travenous immunoglobulin (rIVIG) proteins and methods for purification and use of rIVIG pro- teins. The compositions comprise oligomeric Fc P700511 iiii Chi .: 043 p v : : molecules which bind to Fc receptors with high P80022 r - r.IIT T - air .1 ''' ek2 7 , 51T iiiiroiiFT avidity. The rIVIG proteins are useful as immun- °modulatory molecules for the treatment of im- P8002Z IL .q 4 . - 2.. 1 .c.ta. RR jP...91.: 2 ,.. P2003Z .A. ,k i ai :i II..R.[ Ziii Ii 1.. ail oy g o. mune disorders including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuro - P 80042 ItiL clf?.. „ „ ili?.. \"' !Al.?.. LH?: :11{.Pk...?.. pathy, multiple sclerosis, lupus, Graves Disease, Kawasaki disease, dermatomyositis, myasthenia MOM .gl2i!...H1. .g. 'i.. ffik ,it SAC c9....M14..... 0.4.. .01: gravis, Guillam-Bane syndrome, autoimmune hemolytic anemia, and other immune and inflam- Structural components matory conditions. The rIVIG proteins can also be Human hg kappa light chain constant region ' Human 101 hinge used as immunomodulators in patients to reduce 11 L cli Hunan 1261 heavy chain constant region 1 LIj (GGGGSit the immune rejection of organ transplants, stem ._ N.. _: Hunan IgG1Ixakry chain constant region 2 (GGGGS)/ cell transplants and bone marrow transplantation. M ....m.... Human IgG1 heavy crialn constant region 2 (GGGGSk, ORE CD40 Ilgargleach\"acellular domain (GGGGSh Additionally, the present invention provides rIVIG kr) Collagen XXI GPI repeat • nca domain - c ann a:: : . proteins of non-human origin, for use in veterinary pt immune oxia. Mannose binding domain disorders, such as canine rIVIG proteins N protein trimeriting IN for the treatment of dogs suffering from autoim- mune hemolytic anemia, immune thrombocyt- t - - openia purpura, rheumatoid arthritis, or other can- 11 ine immune disorder. 0 N C
SG11201808541VA 2016-03-30 2017-03-29 Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use SG11201808541VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662315483P 2016-03-30 2016-03-30
PCT/US2017/024650 WO2017172853A1 (en) 2016-03-30 2017-03-29 Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use

Publications (1)

Publication Number Publication Date
SG11201808541VA true SG11201808541VA (en) 2018-10-30

Family

ID=59965144

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808541VA SG11201808541VA (en) 2016-03-30 2017-03-29 Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use

Country Status (18)

Country Link
US (2) US11304994B2 (en)
EP (1) EP3436484A4 (en)
JP (1) JP7075100B2 (en)
KR (1) KR102477536B1 (en)
CN (1) CN109312000A (en)
AU (1) AU2017245143B2 (en)
BR (1) BR112018070022A2 (en)
CA (1) CA3019530A1 (en)
CL (1) CL2018002769A1 (en)
CO (1) CO2018011457A2 (en)
EA (1) EA201891999A1 (en)
IL (1) IL261968A (en)
MA (1) MA44517A (en)
MX (1) MX2018011865A (en)
SG (1) SG11201808541VA (en)
TW (1) TWI801336B (en)
WO (1) WO2017172853A1 (en)
ZA (1) ZA201806767B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004550A (en) 2017-12-14 2020-11-27 康诺贝林伦瑙有限公司 Recombinant IgG Fc multimer for treating neuromyelitis optica
US20210353752A1 (en) * 2018-10-11 2021-11-18 Momenta Pharmaceuticals, Inc. Treatment with highly silylated igg compositions
AU2019360271A1 (en) * 2018-10-18 2021-04-29 Elanco Us Inc. Fc variants with altered binding to neonatal Fc receptor (FcRn) for veterinary use
CN109793894A (en) * 2019-04-03 2019-05-24 长春西诺生物科技有限公司 Application of the dog immunoglobulin in preparation dog hemolytic anemia drug
JP2022547692A (en) 2019-09-13 2022-11-15 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Recombinant IgG Fc Multimers for Treatment of Immune Complex-Mediated Kidney Injury
CN112899301B (en) * 2021-01-29 2023-04-11 中国热带农业科学院热带生物技术研究所 Cassava common mosaic virus induced gene silencing system and application thereof
CN115724988B (en) * 2021-08-26 2023-11-17 瑅安生物医药（杭州）有限公司 Polypeptide fusion molecule close to natural molecule

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1106846C (en) * 1997-08-21 2003-04-30 宝酒造株式会社 Carcinostatic agents
DE19963859A1 (en) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- or oligomer of a di-, tri-, quattro- or pentamer of recombinant fusion proteins
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
CA2437958C (en) 2001-03-09 2018-10-30 University Of Chicago Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors
US7279329B2 (en) * 2005-10-17 2007-10-09 Industrial Technology Research Institute Expression system for producing collagen
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2641913B1 (en) * 2007-06-01 2018-04-18 University of Maryland, Baltimore Immunoglobulin constant region Fc receptor binding agents
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
TWI588157B (en) 2010-07-28 2017-06-21 吉林尼克公司 Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
EP2561888A1 (en) 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
TWI476001B (en) 2011-12-26 2015-03-11 Ind Tech Res Inst Trimeric fc fusion and uses thereof
AU2013295647B2 (en) * 2012-07-26 2018-02-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
MX2015002269A (en) 2012-08-20 2015-07-06 Gliknik Inc Molecules with antigen binding and polyvalent fc gamma receptor binding activity.
EP2908914B1 (en) 2012-10-17 2018-04-18 Liverpool School of Tropical Medicine Immunomodulatory proteins
HUE060464T2 (en) 2013-03-13 2023-03-28 Genzyme Corp Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
BR112016023948A2 (en) 2014-04-16 2018-01-30 Ucb Biopharma Sprl multimeric fc proteins
CN108289928A (en) 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 Improved microorganism-binding molecule and its purposes

Also Published As

Publication number Publication date
AU2017245143A1 (en) 2018-10-18
US11801286B2 (en) 2023-10-31
EP3436484A4 (en) 2019-12-04
CN109312000A (en) 2019-02-05
BR112018070022A2 (en) 2019-02-05
CA3019530A1 (en) 2017-10-05
WO2017172853A1 (en) 2017-10-05
JP7075100B2 (en) 2022-05-25
MX2018011865A (en) 2019-03-28
TWI801336B (en) 2023-05-11
EA201891999A1 (en) 2019-08-30
TW201741335A (en) 2017-12-01
JP2019513024A (en) 2019-05-23
US20220233658A1 (en) 2022-07-28
MA44517A (en) 2019-02-06
KR20180132731A (en) 2018-12-12
CL2018002769A1 (en) 2018-12-28
US11304994B2 (en) 2022-04-19
EP3436484A1 (en) 2019-02-06
KR102477536B1 (en) 2022-12-13
CO2018011457A2 (en) 2019-02-08
ZA201806767B (en) 2023-04-26
US20190111115A1 (en) 2019-04-18
IL261968A (en) 2018-10-31
AU2017245143B2 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
SG11201808541VA (en) Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201908540PA (en) Stable antibody formulation
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201909646TA (en) Trem2 antigen binding proteins and uses thereof
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201807590SA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201906264YA (en) Improved serum albumin binders
SG11201803975SA (en) Improved tnf binders
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201906341XA (en) Improved serum albumin binders
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201811737SA (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201907646YA (en) Proteins binding her2, nkg2d and cd16